报价延迟最少15分钟:2025/07/14 08:04 EDT
盘前时段
|
||||
|
7.76 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
7.49
|
|
|
| 价值评估 |
|
盈利(现时/预测)
0.02/-4.53
|
|
企业价值
708.91M
|
| 资产负债 |
|
每股账面净值
0.75
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
105.76M
|
|
每股收益
1.12
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/07/14 08:04 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenuefrom the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other. |
